Neoadjuvant durvalumab plus radiation versus durvalumab alone in stages I-III non-small cell lung cancer: survival outcomes and molecular correlates of a randomized phase II trial.
Altorki NK, Walsh ZH, Melms JC, Port JL, Lee BE, Nasar A, Spinelli C, Caprio L, Rogava M, Ho P, Christos PJ, Saxena A, Elemento O, Bhinder B, Ager C, Amin AD, Sanfilippo NJ, Mittal V, Borczuk AC, Formenti SC, Izar B, McGraw TE.
Altorki NK, et al. Among authors: nasar a.
Nat Commun. 2023 Dec 19;14(1):8435. doi: 10.1038/s41467-023-44195-x.
Nat Commun. 2023.
PMID: 38114518
Free PMC article.